The invention provides methods for prognosis, diagnosis, staging and determining disease progression in human cancer patients related to expression levels of one or a plurality of genes or genetic loci that are differentially deleted, amplified, expressed or amplified and over-expressed in chemotherapeutic drug resistant tumor cells.